[1] Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol, 2022,22(7):429-443. [2] Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet, 2021,397(102):2212-2224. [3] 卫栋萍,韩黎黎,凌佳慧,等.甘草酸二胺与复方甘草酸苷治疗环磷酰胺所致的药物性肝损伤患者疗效研究.实用肝脏病杂志, 2023, 26(3):388-391. [4] Mou Y, Liao W, Li Y, et al. Glycyrrhizin and the related preparations: an inspiring resource for the treatment of liver diseases. Am J Chin Med,2024,52(2):315-354. [5] Du Y, Song W, Xiong X, et al. Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients. Xenobiotica,2022,52(3):274-283. [6] Qu J, Bian R, Liu B, et al. The pharmacokinetic study of tacrolimus and Wuzhi capsule in Chinese liver transplant patients. Front Pharmacol, 2022,13:956166. [7] 蔡宇,王孟春,邱新平,等.复方甘草酸苷联合丁二磺酸腺苷蛋氨酸治疗酒精性肝炎伴胆汁淤积患者疗效研究.实用肝脏病杂志, 2021,24(1):71-74. [8] Kang SH, Lee HW, Yoo JJ, et al. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin MolHepatol,2021,27(3):363-401. [9] Kudo M, Matilla A, Santoro A, et al. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol,2021,75(3):600-609. [10] 徐亮,宓余强.慢性乙型肝炎合并非酒精性脂肪性肝病的特征及诊治对策.中华肝脏病杂志, 2020, 28(3):198-202. [11] Tincopa MA, Loomba R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol, 2023,8(7):660-670. [12] Chen S, Cao W, Xiao X, et al. A systematic review and meta-analysis of efficacy and safety of compound glycyrrhizin combined with second-generation non-sedated antihistamine for the treatment of chronic urticaria. J Dermatolog Treat,2024,35(1):229-231. [13] 蔡宜朋,谢培华,陈泉金,等.五酯胶囊对他克莫司相关肝功能异常的影响及其与ABCB1基因多态性的关系.中华器官移植杂志, 2020, 41(11):681-686. [14] Fraile JM, Palliyil S, Barelle C,et al. Non-alcoholic steatohepatitis (NASH)-a review of a crowded clinical landscape, driven by a complex disease. Drug Des Devel Ther,2021,22(15):3997-4009. [15] Kannt A, Wohlfart P, Madsen AN, et al. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. Br J Pharmacol, 2021,178(12):2412-2423. [16] Jing Y, Kong Y, Hou X, et al. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients. J Clin Pharm Ther, 2021,46(4):1117-1128. [17] Tovo CV, de Mattos AZ, Coral GP, et al. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. World J Gastroenterol,2023,29(2):343-356. [18] 季旻游,李超,赵兴忠,等.恩替卡韦联合复方甘草酸苷治疗乙型肝炎肝硬化患者疗效及对肠道菌群的影响.实用肝脏病杂志, 2021, 24(5):641-644. [19] Cheng F, Li Q, Wang J, et al. Genetic polymorphisms affecting tacrolimus metabolism and the relationship to post-transplant outcomes in kidney transplant recipients. Pharmgenomics Pers Med,2021,19(14):1463-1474. [20] Chen X, Wang DD, Xu H, et al. Population pharmacokinetics and pharmacogenomics of tacrolimus in Chinese children receiving a liver transplant: initial dose recommendation. Transl Pediatr,2020,9(5):576-586. |